Keywords
Last Name
Institution

Ki Young Chung

Title
InstitutionMedical University of South Carolina
DepartmentHematology/Oncology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Edenfield WJ, Chung K, O'Rourke M, Cull E, Martin J, Bowers H, Smith W, Gluck WL. A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 Apr 23. PMID: 33893692.
      View in: PubMed
    2. Chung KY, Saito K, Zergebel C, Hollywood E, Segal M, Saltz LB. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72. PMID: 21968463.
      View in: PubMed
    3. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90. PMID: 20498386.
      View in: PubMed
    4. Reidy DL, Chung KY, Timoney JP, Park VJ, Hollywood E, Sklarin NT, Muller RJ, Saltz LB. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 Jul 01; 25(19):2691-5. PMID: 17602073.
      View in: PubMed
    5. Chung KY, Saltz LB. Adjuvant therapy of colon cancer: current status and future directions. Cancer J. 2007 May-Jun; 13(3):192-7. PMID: 17620769.
      View in: PubMed
    6. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007 Feb; 14(2):759-65. PMID: 17103075.
      View in: PubMed
    7. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist. 2005 Oct; 10(9):701-9. PMID: 16249350.
      View in: PubMed
    8. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, Gerald W, Chen B. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005 Oct; 18(10):1350-6. PMID: 15832190.
      View in: PubMed
    9. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005 Aug 17; 97(16):1221-4. PMID: 16106027.
      View in: PubMed
    10. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20; 23(9):1803-10. PMID: 15677699.
      View in: PubMed
    Chung's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description